Ginkgo Bioworks Holdings Net Income
| DNA Stock | USD 9.29 0.50 5.69% |
As of the 15th of February 2026, Ginkgo Bioworks retains the Risk Adjusted Performance of 0.0414, market risk adjusted performance of 0.069, and Downside Deviation of 4.34. Ginkgo Bioworks technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Ginkgo Bioworks Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.9007 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -492.3 M | -516.9 M | |
| Net Loss | -492.3 M | -516.9 M | |
| Net Loss | -492.3 M | -516.9 M | |
| Net Loss | (9.49) | (9.96) | |
| Net Income Per E B T | 1.15 | 1.10 |
Ginkgo | Net Income | Build AI portfolio with Ginkgo Stock |
Analyzing Ginkgo Bioworks's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Ginkgo Bioworks's current valuation and future prospects.
Latest Ginkgo Bioworks' Net Income Growth Pattern
Below is the plot of the Net Income of Ginkgo Bioworks Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ginkgo Bioworks Holdings financial statement analysis. It represents the amount of money remaining after all of Ginkgo Bioworks Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ginkgo Bioworks' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ginkgo Bioworks' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (547.03 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Ginkgo Net Income Regression Statistics
| Arithmetic Mean | (453,177,736) | |
| Coefficient Of Variation | (135.72) | |
| Mean Deviation | 431,185,423 | |
| Median | (119,327,000) | |
| Standard Deviation | 615,070,955 | |
| Sample Variance | 378312.3T | |
| Range | 2B | |
| R-Value | (0.51) | |
| Mean Square Error | 298819.4T | |
| R-Squared | 0.26 | |
| Significance | 0.04 | |
| Slope | (62,046,497) | |
| Total Sum of Squares | 6052996.5T |
Ginkgo Net Income History
Other Fundumenentals of Ginkgo Bioworks Holdings
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Ginkgo Bioworks Net Income component correlations
Ginkgo Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ginkgo Bioworks is extremely important. It helps to project a fair market value of Ginkgo Stock properly, considering its historical fundamentals such as Net Income. Since Ginkgo Bioworks' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ginkgo Bioworks' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ginkgo Bioworks' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. Projected growth potential of Ginkgo fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ginkgo Bioworks assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.18) | Revenue Per Share | Quarterly Revenue Growth (0.56) | Return On Assets | Return On Equity |
Understanding Ginkgo Bioworks Holdings requires distinguishing between market price and book value, where the latter reflects Ginkgo's accounting equity. The concept of intrinsic value - what Ginkgo Bioworks' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Ginkgo Bioworks' price substantially above or below its fundamental value.
It's important to distinguish between Ginkgo Bioworks' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ginkgo Bioworks should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Ginkgo Bioworks' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Ginkgo Bioworks 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ginkgo Bioworks' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ginkgo Bioworks.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Ginkgo Bioworks on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Ginkgo Bioworks Holdings or generate 0.0% return on investment in Ginkgo Bioworks over 90 days. Ginkgo Bioworks is related to or competes with Iovance Biotherapeutics, Replimune, MBX Biosciences, MeiraGTx Holdings, ArriVent BioPharma, Maravai Lifesciences, and Vir Biotechnology. Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming More
Ginkgo Bioworks Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ginkgo Bioworks' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ginkgo Bioworks Holdings upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.34 | |||
| Information Ratio | 0.0263 | |||
| Maximum Drawdown | 30.46 | |||
| Value At Risk | (6.36) | |||
| Potential Upside | 8.31 |
Ginkgo Bioworks Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ginkgo Bioworks' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ginkgo Bioworks' standard deviation. In reality, there are many statistical measures that can use Ginkgo Bioworks historical prices to predict the future Ginkgo Bioworks' volatility.| Risk Adjusted Performance | 0.0414 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.17) | |||
| Sortino Ratio | 0.0289 | |||
| Treynor Ratio | 0.059 |
Ginkgo Bioworks February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0414 | |||
| Market Risk Adjusted Performance | 0.069 | |||
| Mean Deviation | 3.39 | |||
| Semi Deviation | 4.18 | |||
| Downside Deviation | 4.34 | |||
| Coefficient Of Variation | 2439.76 | |||
| Standard Deviation | 4.77 | |||
| Variance | 22.74 | |||
| Information Ratio | 0.0263 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.17) | |||
| Sortino Ratio | 0.0289 | |||
| Treynor Ratio | 0.059 | |||
| Maximum Drawdown | 30.46 | |||
| Value At Risk | (6.36) | |||
| Potential Upside | 8.31 | |||
| Downside Variance | 18.86 | |||
| Semi Variance | 17.44 | |||
| Expected Short fall | (3.49) | |||
| Skewness | 1.27 | |||
| Kurtosis | 4.9 |
Ginkgo Bioworks Holdings Backtested Returns
Ginkgo Bioworks appears to be slightly risky, given 3 months investment horizon. Ginkgo Bioworks Holdings holds Efficiency (Sharpe) Ratio of 0.0822, which attests that the entity had a 0.0822 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Ginkgo Bioworks Holdings, which you can use to evaluate the volatility of the firm. Please utilize Ginkgo Bioworks' Downside Deviation of 4.34, risk adjusted performance of 0.0414, and Market Risk Adjusted Performance of 0.069 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Ginkgo Bioworks holds a performance score of 6. The company retains a Market Volatility (i.e., Beta) of 3.14, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ginkgo Bioworks will likely underperform. Please check Ginkgo Bioworks' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Ginkgo Bioworks' current trending patterns will revert.
Auto-correlation | 0.59 |
Modest predictability
Ginkgo Bioworks Holdings has modest predictability. Overlapping area represents the amount of predictability between Ginkgo Bioworks time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ginkgo Bioworks Holdings price movement. The serial correlation of 0.59 indicates that roughly 59.0% of current Ginkgo Bioworks price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.59 | |
| Spearman Rank Test | -0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.27 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ginkgo Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ginkgo Bioworks Holdings reported net income of (547.03 Million). This is 260.29% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 195.81% higher than that of the company.
Ginkgo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ginkgo Bioworks' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ginkgo Bioworks could also be used in its relative valuation, which is a method of valuing Ginkgo Bioworks by comparing valuation metrics of similar companies.Ginkgo Bioworks is currently under evaluation in net income category among its peers.
Ginkgo Bioworks ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ginkgo Bioworks' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ginkgo Bioworks' managers, analysts, and investors.Environmental | Governance | Social |
Ginkgo Bioworks Institutional Holders
Institutional Holdings refers to the ownership stake in Ginkgo Bioworks that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Ginkgo Bioworks' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ginkgo Bioworks' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 937.6 K | Prescott Group Capital Management Llc | 2025-06-30 | 775.6 K | State Street Corp | 2025-06-30 | 741.1 K | Sb Investment Advisers (uk) Ltd | 2025-06-30 | 610.7 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 509.5 K | Opaleye Management Inc | 2025-06-30 | 500 K | Jump Financial Llc | 2025-06-30 | 370 K | Charles Schwab Investment Management Inc | 2025-06-30 | 331.5 K | Ensign Peak Advisors Inc | 2025-06-30 | 330.9 K | Viking Global Investors Lp | 2025-06-30 | 3.6 M | Baillie Gifford & Co Limited. | 2025-06-30 | 3.3 M |
Ginkgo Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.88) % | ||||
| Operating Margin | (2.27) % | ||||
| Current Valuation | 523.89 M | ||||
| Shares Outstanding | 48.52 M | ||||
| Shares Owned By Insiders | 3.46 % | ||||
| Shares Owned By Institutions | 75.99 % | ||||
| Number Of Shares Shorted | 6.7 M | ||||
| Price To Earning | 25.51 X | ||||
| Price To Book | 1.01 X | ||||
| Price To Sales | 3.12 X | ||||
| Revenue | 227.04 M | ||||
| Gross Profit | 131.31 M | ||||
| EBITDA | (484.39 M) | ||||
| Net Income | (547.03 M) | ||||
| Cash And Equivalents | 561.57 M | ||||
| Cash Per Share | 0.84 X | ||||
| Total Debt | 467.73 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 11.84 X | ||||
| Book Value Per Share | 9.85 X | ||||
| Cash Flow From Operations | (319.58 M) | ||||
| Short Ratio | 7.81 X | ||||
| Earnings Per Share | (6.18) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 834 | ||||
| Beta | 1.56 | ||||
| Market Capitalization | 562.88 M | ||||
| Total Asset | 1.38 B | ||||
| Retained Earnings | (5.84 B) | ||||
| Working Capital | 495.48 M | ||||
| Current Asset | 10.07 B | ||||
| Current Liabilities | 3.1 B | ||||
| Net Asset | 1.38 B |
About Ginkgo Bioworks Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ginkgo Bioworks Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ginkgo Bioworks using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ginkgo Bioworks Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ginkgo Bioworks Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ginkgo Bioworks' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ginkgo Bioworks Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ginkgo Bioworks Holdings Stock:Check out You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. Projected growth potential of Ginkgo fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ginkgo Bioworks assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.18) | Revenue Per Share | Quarterly Revenue Growth (0.56) | Return On Assets | Return On Equity |
Understanding Ginkgo Bioworks Holdings requires distinguishing between market price and book value, where the latter reflects Ginkgo's accounting equity. The concept of intrinsic value - what Ginkgo Bioworks' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Ginkgo Bioworks' price substantially above or below its fundamental value.
It's important to distinguish between Ginkgo Bioworks' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ginkgo Bioworks should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Ginkgo Bioworks' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.